Patent ID: 6582919
Filing Date: 2003-06-24
Classification: C12Q

Abstract:
A method for determining a chemotherapeutic regimen comprising a receptor tyrosine kinase targeted agent, for treating a tumor in a patient comprising:(a) obtaining a tissue sample of the tumor; (b) obtaining a matching non-malignant tissue sample; (c) isolating mRNA from the tumor sample and non-malignant sample; (d) subjecting the mRNA to amplification using a pair of oligonucleotide primers capable of amplifying a region of the EGFR gene, or a pair of oligonucleotide primers capable of amplifying a region of the HER2-neu gene, to obtain an EGFR tumor amplified sample and a EGFR non-malignant amplified sample, or a HER2-neu tumor amplified sample and a HER2-neu non-malignant amplified sample (e) determining an amount of HER2-neu mRNA in the HER2-neu tumor amplified sample and HER2-neu non-malignant amplified sample or determining the amount of EGFR mRNA in the EGFR tumor amplified sample and EGFR non-malignant amplified sample; (f) obtaining a differential HER2-neu epression level or obtaining a differential EGFR expression level; and (g) determining a chemotherapeutic regimen comprising a receptor tyrosine kinase targeted agent by comparing the differential HER2-neu expression level of step (f) and a threshold level for differential HER2-neu gene expression, or comparing the differential EGFR expression level of step (f) and a threshold level for differential EGFR gene expression.